Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Jing Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, “off-the-shelf” universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeting. Major developments and updates for the therapy of hematological malignancies were delineated at the recent Winter Symposium and New York Oncology Forum from the Chinese American Hematologist and Oncologist Network (CAHON.org). This study summarized the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.

Original languageEnglish (US)
Article number66
JournalJournal of Hematology and Oncology
Volume14
Issue number1
DOIs
StatePublished - Dec 2021

Keywords

  • Antibody–drug conjugate
  • Asciminib
  • BCMA
  • BiTE
  • CAR-T
  • LOXO-305

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting'. Together they form a unique fingerprint.

Cite this